newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards

  • AEON Biopharma, Inc. (NYSE: AEON) received written notice from NYSE American LLC confirming it has regained compliance with stockholders' equity listing standards.
  • The Company resolved deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide, prompting the removal of the ".BC" indicator from its trading symbol.
  • Compliance was achieved following an underwritten public offering closed on July 15, 2026, involving 17,851,599 shares & pre-funded warrants for 24,837,008 shares.
  • On July 23, 2026, AEON sold an additional 4,696,102 shares via a partial exercise of the underwriters' over-allotment option.
  • The Offering generated approximately $13.6 million in net proceeds, with potential for up to $34.0 million in additional gross proceeds from full cash exercise of milestone warrants.
  • Proceeds from the Offering, which closed after the second fiscal quarter, will be reflected as a subsequent event in the upcoming Form 10-Q, while the June 30, 2026 balance sheet will show a stockholders' deficit.
  • AEON's lead asset, ABP-450, is a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use, with development & distribution rights in the U.S., Canada, the EU, the UK, & other territories.
  • ABP-450 is already approved as a biosimilar in India, Mexico, & the Philippines & is manufactured by Daewoong Pharmaceutical in a facility approved by the U.S. FDA, Health Canada, & the European Medicines Agency.
  • The Company remains subject to standard NYSE American monitoring procedures & is committed to maintaining financial discipline & governance.